Optimizing Clinical Monitoring and Management Guidelines for Capivasertib in HR-Positive/HER2-Negative Advanced Breast Cancer: Expert Opinion

December 2025 in “ npj Breast Cancer ”

Neil M. Iyengar, Joyce O’Shaughnessy, Heather Moore, Erika Hamilton, Komal Jhaveri, X. Cynthia, Karen L. Tedesco, Monali Vasekar, Sarah Donahue, Hope S. Rugo

TLDR Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Capivasertib, an AKT inhibitor, has been approved for use with fulvestrant in treating hormone receptor-positive, HER2-negative advanced breast cancer with specific genetic alterations, showing significant improvement in progression-free survival in the CAPItello-291 phase 3 trial. However, it is associated with adverse events such as diarrhea, rash, and hyperglycemia, which necessitate proactive management. The article offers practical recommendations for prevention and early intervention to enhance adherence and treatment outcomes.

View this study on nature.com →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Managing Hyperglycemia and Rash Associated With Alpelisib: Expert Consensus Recommendations Using the Delphi Technique

1 citations , January 2024 in “NPJ breast cancer”

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines

86 citations , November 2020 in “Annals of Oncology”

Early intervention and tailored management can reduce skin side effects from cancer treatments.